A carregar...
Physician experiences with sodium-glucose cotransporter (SGLT2) inhibitors, a new class of medications in type 2 diabetes, and adverse effects
AIM: The primary aim of our study is to identify physicians who have witnessed a complication attributed to sodium-glucose cotransporter (SGLT2) inhibitors. The secondary aim is to determine the type, severity, and setting of the event (inpatient versus outpatient). BACKGROUND: Diabetes is an increa...
Na minha lista:
| Publicado no: | Prim Health Care Res Dev |
|---|---|
| Main Authors: | , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Cambridge University Press
2018
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6567894/ https://ncbi.nlm.nih.gov/pubmed/30032729 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1017/S1463423618000476 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|